Company intelligence / Profile preview

EndoStream Medical

Ownership: Private
Development stage: Commercial

Overview

EndoStream Medical developed the Nautilus™, an innovative self-conforming intrasaccular flow diverter designed to treat wide-necked brain aneurysms. The device received European regulatory approval in November 2024 and has begun commercialization there. Clinical trials are underway in the United States with plans for market entry by spring 2026, followed by Japan. The Nautilus™ system can be used with embolization coils to improve treatment outcomes for complex cerebral aneurysms that are difficult to treat with existing technologies.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Nautilus

Commercial

Indications: Brain aneurysm

Partnerships

Kaneka Corporationdistribution partnership with Kaneka Neurovascular USA for related products like i‑ED COIL™

Beyond the preview

Go deeper on EndoStream Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EndoStream Medical.

Explore the full profile